BC Week In Review | Apr 6, 2017
Company News

Ogeda, Astellas deal

Astellas will acquire Ogeda, giving the pharma neurokinin 3 receptor ( TACR3 ; NK3R) antagonist fezolinetant (ESN364). The candidate has met the primary endpoints in a Phase IIa trial to treat hot flashes. Ogeda said it...
Items per page:
1 - 1 of 1